• Warren Buffett
  • Volvo
  • NASDAQ Composite Index
  • 10 Year Treasury
  • Commercial Banks
  • JPMorgan Chase
  • Emerging Markets
  • Commerce Department
  • Stock Market
  • Home
  • Practice Management
  • Research & Insights
  • Alternatives
  • ETF Managed Portfolios
  • Home>Research & Insights>Sector Rap>The Future of Big Pharma

    Related Content

    1. Videos
    2. Articles
    1. What's Behind All These Health-Care Deals?

      Recent M&A activity among health-care stocks indicates firms are homing in on core competencies and cost savings, but stock-buying ideas remain unclear.

    2. Winners and Losers in the Drug-Pricing War

      Major pharmacy benefit managers and pharma stocks with innovative pipelines should see the most upside, while companies that rely heavily on price increases for growth will likely suffer, says Morningstar's Matt Coffina.

    3. The Friday Five

      Bank of America makes a boo-boo, Twitter shares are still flying too high, Morningstar heads to Omaha, and more.

    4. When Stocks Are Safer

      Data show that the longer investors held stocks (and stomached short-term volatility), the safer they became for meeting portfolio objectives, says Morningstar's David Blanchett.

    The Future of Big Pharma

    Things look grim, but investors who can bear it could benefit.

    Haywood Kelly, 04/01/2009

    Big pharmaceutical stocks are divisive. Some analysts think that they're trading at bargain prices and provide a great place to ride out the global economic crisis. Others think that they deserve to be cheap and might get a lot cheaper as politicians set their sights on health-care reform. To get a better feel for the sector, I talked to Damien Conover, who is a senior analyst on Morningstar's health-care team. Conover covers such names as Johnson & Johnson JNJ, Merck MRK, Pfizer PFE, Abbott Laboratories ABT, and Novartis NVS. He also heads up the monthly Morningstar Healthcare Observer newsletter, which provides in-depth research on the health-care sector.

    Haywood Kelly: Damien, you're bullish on pharmaceutical stocks, but let's start off with the bear case. How bad could things get over the next few years?

    Damien Conover: The pharmaceutical group faces some significant near-term head winds. With a major patent cliff approaching the industry in 2010, a strong bear case can be made for the stocks. Approximately $60 billion of drug sales go generic between 2010 and 2012. The lost sales magnify the importance of developing new drugs to fill the void created by the generic competition. Drug companies, however, have failed to bring the next generation of new drugs to the market. Another issue is that, after the market withdrawal of Merck's pain drug, Vioxx, the Food and Drug Administration became risk averse and has rejected many new drugs. Because of the lack of new medicines, the earnings for several pharmaceutical companies are expected to shrink in the next few years. The poor earnings outlook has caused the earnings multiples on the drug stocks to fall to historic lows.

    HK: And there's the new administration in Washington.

    DC: New government regulations proposed by the Obama administration could reduce the pricing power of pharmaceutical companies. The new administration supports a host of policies that will threaten drug prices: increased insurance coverage, direct price negotiation for Medicare Part D, generic biologics, drug re-importation, and comparative effectiveness programs. Of these, I'd highlight increased governmental insurance coverage in particular, which will bring a major payer to the table. Because of its massive size and authority, the government will likely demand and receive lower drug prices.

    And we can't ignore the fact that the consolidation and growth of managed care have reduced the pricing power of less innovative drugs. From the 1990s through the beginning of this decade, drug companies could easily price "follow-on," or "me-too," drugs (treatments that differ little from existing drugs) at the similar or even higher prices than comparable drugs. In 2001, for example, heartburn drug Nexium was launched and replaced most of the sales from its predecessor, Prilosec, even though Prilosec was facing generic competition and Nexium offered little differentiation. It is hard to believe that in today's landscape, managed care would offer such accommodative reimbursement to a drug with little new to offer. We've already begun to see this with managed care's reluctance to provide favorable reimbursement to Prisiq, Wyeth's antidepressant drug. So far, it has generated lackluster results.PAGEBREAK

    HK: You've succeeded in painting a bleak picture. Now, how much of that is priced into the stocks?

    DC: Almost all of the challenges facing the industry have been factored into the stocks. The implications of new government health- care reforms have largely been blown out of proportion. The industry might lose some pricing power, but 50 million newly insured customers should counterbalance it.